A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia

@inproceedings{Adams2013ALP,
  title={A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia},
  author={David H Adams and Bruce J. Kinon and Simin K. Baygani and Brian A. Millen and Isabella Velon{\`a} and Sara Kollack-Walker and David P Walling},
  booktitle={BMC psychiatry},
  year={2013}
}
BACKGROUND We compared the time to discontinuation due to lack of tolerability over 24 weeks in patients suffering from schizophrenia treated with pomaglumetad methionil (LY2140023 monohydrate, the prodrug of metabotropic glutamate 2/3 receptor agonist, LY404039) or standard of care (SOC: olanzapine, risperidone, or aripiprazole). METHODS Study HBBR was a multicenter, randomized, open-label study comparing the long-term safety and tolerability of LY2140023 with SOC for schizophrenia. Patients… CONTINUE READING
28 Citations
10 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 10 references

ECDEU Assessment Manual for Psychopharmacology, Revised (Publication ADM 76–338)

  • W Guy
  • US Dept of Health,
  • 1976
1 Excerpt

Similar Papers

Loading similar papers…